Verified factor-similar pair

SLYG vs UPGD

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
86
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • SLYG has the higher backtested relative Sharpe (0.646 vs 0.583).
  • SLYG has the lower published fee (0.15% vs 0.40%).
  • UPGD is cheaper on dividend valuation (64 vs 143, where 100 is each fund's historical median).
  • SLYG has the stronger regression fit (adjusted R-squared 0.928 vs 0.880).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

SLYG

State Street SPDR S&P 600 Small Cap Growth ETF
SMB
Adj. R2
0.928
Rel. Sharpe
0.646
Mkt beta
1.04
AUM
US$4.2B
MER
0.15%
Valuation
143

UPGD

Invesco Bloomberg Analyst Rating Improvers ETF
SMB
Adj. R2
0.880
Rel. Sharpe
0.583
Mkt beta
1.06
AUM
US$110M
MER
0.40%
Valuation
64

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
SLYG
+0.76
|t|
+19.5
UPGD
+0.65
|t|
+10.6
diff +0.11
HML
SLYG
-0.05
|t|
-1.2
UPGD
+0.06
|t|
+1.1
diff -0.11
RMW
SLYG
-0.13
|t|
-2.9
UPGD
+0.07
|t|
+0.9
diff -0.19
CMA
SLYG
-0.04
|t|
-0.6
UPGD
+0.02
|t|
+0.2
diff -0.05
UMD
SLYG
-0.03
|t|
-1.4
UPGD
-0.06
|t|
-1.7
diff +0.03

Why This Pair Matches

Exposure level
83
Exposure shape
97
Mkt beta diff
0.02
Rel. Sharpe diff
0.063

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

SLYG fund page UPGD fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.